6000 Shoreline Court
South San Francisco
288 articles with Veracyte, Inc.
Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 3:00 p.m. Eastern Time.
Veracyte, Inc. announced financial results for the first quarter ended March 31, 2020 and provided an update on recent business progress.
Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis
Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
April 23, 2020 12:15 UTC - Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.--( BUSINESS WIRE )-- Veracyte, Inc. (Nasdaq: VCYT) and Yale University today announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF). The agreement gives Veracyte rights to a 52-gene signature developed by Yale
CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
Veracyte, Inc. (Nasdaq: VCYT) and Yale University announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF).
Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic
Expects first quarter revenue in the range of $30.5 million to $31.5 million Withdraws full-year 2020 guidance
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients Company launches expanded content to detect novel NTRK, ALK, RET and BRAF fusions at time of diagnosis SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Veracyte, Inc. (Nasdaq: VCYT) today announced results of a study that identified over 100 novel or rare NTRK, ALK, RET and BRAF fusions in
Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
Findings Based on Randomized Study of Danish Women with High-Risk, Early Breast Cancer Published in npj Breast Cancer
Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
Veracyte, Inc., announced financial results and business progress for the quarter and full year ended December 31, 2019, and provided financial guidance for 2020.
Feb. 13, 2020 13:15 UTC SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27, 2020 at 10:30 a.m. Eastern Time. The link to the live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at https://investor.ve
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the fourth quarter and full-year 2019 after the close of market on Tuesday, February 25, 2020.
Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion
Under the collaboration deal with Acerta, Veracyte will offer genomic information in support of Acerta’s oncology development program. Financial details were not disclosed.
Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise
Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
Findings Presented at 89th Annual Meeting of the American Thyroid Association
Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples
Veracyte, Inc. announced financial results and business progress for the third quarter ended September 30, 2019.
Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis
Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021
Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive
Data Being Presented at CHEST Annual Meeting 2019
Results From Three Studies Presented at CHEST 2019 Suggest Test Increases Physicians’ Confidence in Diagnosis and Can Reduce the Need for Invasive, Risky Procedures